Combined Inhibition of HDAC and mTOR May Improve Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma
PHILADELPHIA – The histone deacetylase (HDAC) inhibitor vorinostat (Zolinza) in combination with the mTOR inhibitor sirolimus (Rapamune) or everolimus...